Q4 EPS Estimate for BioLife Solutions Decreased by Analyst

BioLife Solutions, Inc. (NASDAQ:BLFS) – Research analysts at Northland Capmk lowered their Q4 2024 earnings estimates for shares of BioLife Solutions in a research report issued to clients and investors on Wednesday, January 8th. Northland Capmk analyst C. Byrnes now expects that the medical equipment provider will earn ($0.04) per share for the quarter, down from their previous forecast of ($0.01). The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.29) per share. Northland Capmk also issued estimates for BioLife Solutions’ Q1 2025 earnings at ($0.03) EPS, Q2 2025 earnings at ($0.02) EPS, Q3 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.05) EPS.

Several other equities analysts have also recently commented on BLFS. Northland Securities upped their price target on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Wednesday, January 8th. Benchmark restated a “buy” rating and issued a $30.00 target price on shares of BioLife Solutions in a research note on Thursday, December 19th. Craig Hallum lifted their price target on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. TD Cowen increased their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, HC Wainwright reduced their price objective on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a report on Monday, November 18th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, BioLife Solutions presently has an average rating of “Moderate Buy” and a consensus target price of $29.43.

BioLife Solutions Stock Performance

Shares of NASDAQ BLFS opened at $26.61 on Monday. BioLife Solutions has a 12 month low of $14.50 and a 12 month high of $28.88. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The company has a market cap of $1.23 billion, a P/E ratio of -25.10 and a beta of 1.92. The business’s 50 day moving average is $26.04 and its two-hundred day moving average is $24.37.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Mark Sheptoff Financial Planning LLC bought a new stake in BioLife Solutions in the third quarter valued at approximately $28,000. Quest Partners LLC acquired a new stake in BioLife Solutions during the 3rd quarter valued at $57,000. GAMMA Investing LLC boosted its position in BioLife Solutions by 29.4% during the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after purchasing an additional 748 shares during the period. Canada Pension Plan Investment Board acquired a new position in shares of BioLife Solutions in the second quarter valued at $122,000. Finally, Arizona State Retirement System bought a new position in shares of BioLife Solutions in the second quarter valued at about $217,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

Insider Buying and Selling at BioLife Solutions

In other news, CFO Troy Wichterman sold 987 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $27.02, for a total transaction of $26,668.74. Following the completion of the transaction, the chief financial officer now directly owns 121,779 shares of the company’s stock, valued at $3,290,468.58. This trade represents a 0.80 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Aby J. Mathew sold 7,604 shares of BioLife Solutions stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $27.33, for a total transaction of $207,817.32. Following the completion of the sale, the executive vice president now owns 276,315 shares in the company, valued at $7,551,688.95. This trade represents a 2.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 113,129 shares of company stock valued at $2,576,818. Company insiders own 2.20% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.